Drug Type Small molecule drug |
Synonyms FC084 Camphor Sulfonate, FC084樟脑磺酸盐, FC084CSA |
Target |
Action inhibitors |
Mechanism AXL inhibitors(AXL receptor tyrosine kinase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 2 | China | 13 Nov 2024 | |
| Breast Cancer | IND Approval | China | 27 Oct 2022 | |
| Liver Cancer | IND Approval | China | 27 Oct 2022 | |
| Non-Small Cell Lung Cancer | IND Approval | China | 27 Oct 2022 | |
| Sarcoma | IND Approval | China | 27 Oct 2022 | |
| Stomach Cancer | IND Approval | China | 27 Oct 2022 |





